IO Biotech gains on agreement with Merck for cancer therapy trial
03/11/2022 15:32
** Shares of biotech co IO Biotech IOBT.O up ~3% at $2.53
in morning trade
** IOBT enters into a clinical trial collaboration and
supply agreement with drugmaker Merck & Co MRK.N urn:newsml:reuters.com:*:nGNXbgHPY6
** Co says will work with MRK to evaluate its lead drug
candidate, IO102-IO103, in combination with MRK's widely-used
cancer therapy Keytruda
** Trial will test combination therapy on patients with
resectable tumors in at least two indications - IOBT
** Under terms, MRK will supply Keytruda for the combination
study which will be sponsored by IOBT
** Including session's move, IOBT down ~61% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))